RT Journal Article SR Electronic T1 Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel JF Open Heart JO Open Heart FD British Cardiovascular Society SP e001592 DO 10.1136/openhrt-2021-001592 VO 8 IS 1 A1 Christopher F Spurney A1 Deborah Ascheim A1 Lawrence Charnas A1 Linda Cripe A1 Kan Hor A1 Nicholas King A1 Kathi Kinnett A1 Elizabeth M McNally A1 John-Michael Sauer A1 Lee Sweeney A1 Chet Villa A1 Larry W Markham YR 2021 UL http://openheart.bmj.com/content/8/1/e001592.abstract AB Cardiac disease is now the leading cause of death in Duchenne muscular dystrophy (DMD). Clinical evaluations over time have demonstrated asymptomatic cardiac troponin elevations and acute elevations are associated with symptoms and cardiac dysfunction in DMD. Clinicians require a better understanding of the relationship of symptoms, troponin levels and progression of cardiac disease in DMD. As clinical trials begin to assess novel cardiac therapeutics in DMD, troponin levels in DMD are important for safety monitoring and outcome measures. The Parent Project Muscular Dystrophy convened an expert panel of cardiologists, scientists, and regulatory and industry specialists on 16 December 2019 in Silver Spring, Maryland and reviewed published and unpublished data from their institutions. The panel recommended retrospective troponin data analyses, prospective longitudinal troponin collection using high-sensitivity cardiac troponin I assays, inclusion of troponin in future clinical trial outcomes and future development of clinical guidelines for monitoring and treating troponin elevations in DMD.